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COST-EFFECTIVENESS ANALYSIS FOR PHARMACOLOGICAL 
INTERVENTION AND COGNITIVE BEHAVIORAL TREATMENT (CBT) 
FOR MAJOR DEPRESSION IN THAILAND
Prukkanone B1, Vos T2, Bertram M2, Burgess P1
1University of Queensland, Brisbane, QLD, Australia, 2The University of Queensland, 
Brisbane, Queensland, Australia
OBJECTIVES: To determine the cost-effectiveness of interventions for major depres-
sion in Thailand. METHODS: A microsimulation model was developed to describe 
the course of disease in individuals. Model inputs included Thai data on disease 
parameters and costs while impact measures are derived from a systematic review and 
meta-analysis of the international literature. Results are presented as cost (Thai Baht) 
per disability adjusted life-year (DALY) averted, compared to the null scenario (do 
nothing). Fluoxetine as the cheapest antidepressant drug in Thailand was analyzed for 
treatment of episodes plus a 6 month continuation phase and for maintenance treat-
ment over 5 years of follow-up. Cognitive behavioral therapy (CBT) was analyzed for 
episodic treatment and for 5-year maintenance treatment. RESULTS: The incremental 
cost-effectiveness ratios (ICER) of ﬂ uoxetine for episodic treatment with or without a 
continuation or maintenance phase are just below one times GDP per capita in Thailand 
of 110,000 Baht. CBT during an episode of depression (ICER = 39,000) is more cost-
effective than medications (ICER = 88,000); a maintenance version of CBT is the most 
cost-effective option with an ICER of 27,000. Episodic drug treatment has the lowest 
cost (250 Million Baht) and averts 3000 DALYs. Episodic treatment with CBT, which 
has an ongoing effect for 1.5 years, costs 100 Million Baht more than drug treatment 
but it averts more than 6000 DALYs compared to drugs. CONCLUSIONS: CBT is the 
most cost-effective treatment option for both episodic and maintenance treatment. 
Maintenance treatment is the more cost-effective of the two. However, there is cur-
rently a lack of mental health personal, especially psychiatrists and psychologists, who 
would be expected to deliver CBT in Thailand. Antidepressant drugs are quite a bit 
less effective but also less costly than CBT. 
PMH12
COST-EFFECTIVENESS OF TYPICALS, ATYPICALS AND PSYCHOSOCIAL 
INTERVENTIONS FOR SCHIZOPHRENIA IN THAILAND
Phanthunane P1, Vos T2, Whiteford H1, Bertram M2
1University of Queensland, Brisbane, QLD, Australia; 2The University of Queensland, 
Brisbane, Queensland, Australia
OBJECTIVES: To determine the optimal treatment package, including drug and non 
drug interventions, for schizophrenia in Thailand. METHODS: A Markov model was 
used to evaluate the cost-effectiveness of typical antipsychotics, generic risperidone, 
olanzapine, clozapine and family interventions. Health outcomes were measured in 
disability adjusted life-years. We considered health outcomes from a change in disease 
severity; extrapyradimal symptoms and weight gain as side effects; and a reduction in 
suicide (for clozapine only). Intervention costs included treatment cost, hospitalization 
cost as well as time and travel cost of patients and families. Uncertainty was evaluated 
using multivariate Monte Carlo simulation. As a generic version of risperidone is 
expected on the market soon, a sensitivity analysis of varying costs of risperidone was 
undertaken. RESULTS: The cost-effectiveness results indicate generic risperidone, 
assuming a cost of 4 baht per 2-mg tablet will improve health outcomes and save costs 
if replacing the currently predominant treatment of typical drugs. The ideal combina-
tion of treatments is risperidone as ﬁ rst line treatment (dominant intervention), adding 
family interventions for all patients (Incremental cost-effectiveness ratio of 2000 baht/
DALY) and adding clozapine to severe patients (an estimated 33% of patients). This 
addition has an incremental cost-effectiveness ratio of 290,000 baht/DALY, which is 
still less than three times GDP per capita. CONCLUSIONS: The introduction of 
generic risperidone will lead to more efﬁ cient outcomes and lower costs if it can be 
produced for less than 10 baht per 2-mg tablet. Providing family interventions for all 
patients and treating more severe patients with clozapine can further improve out-
comes of Thai patients with schizophrenia in a cost-effective manner. 
MENTAL HEALTH – Patient-Reported Outcomes Studies
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ASSOCIATION OF MEDICATION PERSISTENCE AND HEALTH-CARE 
UTILIZATION IN HIGH-COST PATIENTS WITH MAJOR DEPRESSIVE 
DISORDER TREATED WITH DULOXETINE OR VENLAFAXINE XR
Liu X1, Tepper P2, Mullins CD3, Faries D1, Johnstone B1
1Eli Lilly and Company, Indianapolis, IN, USA; 2University of Pittsburgh, Pittsburgh, PA, USA; 
3University of Maryland School of Pharmacy, Baltimore, MD, USA
OBJECTIVES: Adequate duration of antidepressant therapy is essential for the treat-
ment of major depressive disorder (MDD). This study examined the association 
between medication persistence and hospitalization and emergency room (ER) visit 
for high-cost patients with MDD in the usual clinical setting. METHODS: In a large 
US commercial managed-care claims database, 8177 MDD patients (18 to 64 years 
old) were initiated on duloxetine or venlafaxine XR during the calendar year 2006. 
All of the patients had no active prescription of study medications for 6 months prior 
to initiation and had continuous enrollment for 12 months prior to and post-
medication initiation. High-cost patients were deﬁ ned as patients whose total treat-
ment costs in the prior 1 year were above the median of total costs for all MDD 
patients in 2005 (n = 5093). After propensity-score matching on observed variables 
known to affect medication choices, 1714 duloxetine patients and an equal number 
of venlafaxine XR patients were included for this analysis. Medication persistence was 
deﬁ ned as the length of therapy without exceeding a 15-day gap. Logistic regression 
analyses were used to examine the associations between medication persistence and 
health-care utilization in the year following treatment initiation. RESULTS: In the 
post 1 year, duloxetine patients stayed on the medication signiﬁ cantly longer (119.5 
vs. 110.4 days, P = 0.047) than venlafaxine XR patients. Treatment persistence >3 
months was signiﬁ cantly associated with reduced odds of psychiatric hospitalization 
(OR = 0.46, 95% CI = 0.37–0.58), nonpsychiatric hospitalization (OR = 0.77, 95% 
CI = 0.64–0.92), and ER visit (OR = 0.69, 95% CI = 0.60–0.79). Treatment differences 
in health-care utilization were not statistically signiﬁ cant. These ﬁ ndings had no 
essential changes with adjustment for demographics, comorbid conditions, and prior 
health-care utilization and separate analyses for duloxetine and venlafaxine XR 
patients. CONCLUSIONS: Duloxetine therapy appears to have longer persistence 
than venlafaxine XR for high-cost patients with MDD. Medication persistence >3 
months is associated with reduced hospitalization and ER visit. 
PMH14
ADHERENCE AND PERSISTENCE WITH DULOXETINE VERSUS 
ESCITALOPRAM AMONG HIGH HEALTH-CARE RESOURCES UTILIZERS 
WITH MAJOR DEPRESSIVE DISORDER
Tepper P1, Liu X2, Able SL2, Johnstone B2
1University of Pittsburgh, Pittsburgh, PA, USA; 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: Adherence and persistence to prescribed medication is important in 
the management of major depressive disorder (MDD). This study compared adherence 
and persistence between duloxetine and escitalopram among high health-care utilizers 
with MDD. METHODS: In a large US commercial managed-care claims database, 
10,803 MDD patients (18 to 64 years) who initiated on duloxetine (n = 4542) or 
escitalopram (n = 6261) during the calendar year 2006 were identiﬁ ed. All of the 
patients had no recorded prescription of study medications for 6 months prior to 
initiation and had continuous enrollment for 12 months prior to and post-medication 
initiation. High health-care utilizers (duloxetine, n = 3113; escitalopram, n = 3157) 
were deﬁ ned as patients whose total treatment costs in the prior 1 year were above 
the median of total costs for all MDD patients in 2005. Adherence was deﬁ ned as 
Medication Possession Ratio (MPR) ≥0.8, and persistence was deﬁ ned as the length 
of therapy without exceeding a 30-day gap. Statistical analyses included chi-square 
test, Wilcoxon rank sum test, multivariate logistic and Cox regression. RESULTS: In 
the post 6 months (6M) and 12 months (12M), adherence rates were signiﬁ cantly 
higher for duloxetine-treated patients (6M 54.6% and 12M 40.9%) than escitalo-
pram-treated patients (6M 47.4% and 12M 31.7%) (P-values < 0.001). Duloxetine-
treated patients also stayed on the medication signiﬁ cantly longer (6M 115.9 days and 
12M 171.1 days) than escitalopram-treated patients (6M 108.4 days and 12M 154.6 
days) (P-values < 0.001). Results were essentially unchanged with adjustment for 
demographics, comorbid conditions, prior medications use, and health-care utiliza-
tion, resulting in duloxetine therapy maintaining its better adherence and longer 
persistence versus escitalopram. CONCLUSIONS: Duloxetine-treated patients appear 
to be more adherent and have a longer stay on the medication than escitalopram-
treated patients for high resources utilizers. Further research is needed to examine 
clinical and economic beneﬁ ts of better adherence and persistence with duloxetine 
therapy. 
PMH15
THE VALIDATION OF TWO MEASURES ASSESSING REASONS FOR 
ANTIPSYCHOTIC DISCONTINUATION AND CONTINUATION FROM 
PATIENTS’ AND CLINICIANS’ PERSPECTIVES
Faries D, Ascher-Svanum H, Nyhuis A, Anderson J, Phillips G
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: Treatment discontinuation is an important effectiveness measure for 
evaluating antipsychotic treatment, yet is typically assessed only on a high level (e.g., 
“lack of efﬁ cacy,” “adverse event,” or “patient decision”). The RAD-I was developed 
as a structured interview assessing patient’s perspective regarding speciﬁ c reasons for 
antipsychotic discontinuation and continuation and the RAD-Q as a questionnaire 
assessing clinician’s perspective. This study assessed the validity of the RAD measures 
in a randomized clinical trial. METHODS: The RAD was assessed at baseline (refer-
ring to medications prior to the trial) and endpoint (referring to discontinuation/
continuation of study drug) in a 12-week schizophrenia clinical trial. To assess its 
psychometric properties, we examined content validity, discriminate validity, and 
agreement between RAD scales using endpoint data (N = 158). RESULTS: Of 29 
potential primary reasons for medication discontinuation, the most common was 
insufﬁ cient improvement/worsening of positive symptoms (24%) followed by adverse 
events (22%). A high level of concurrent validity was observed, as 89% of patients 
discontinuing medication due to “lack of efﬁ cacy” (87%, “adverse events”) per the 
standard trial form had lack of efﬁ cacy (“adverse events”) as a primary or very 
important reason on the RAD. Patients indicating lack of improvement/worsening of 
positive symptoms as a primary reason for medication discontinuation on the RAD 
had signiﬁ cantly less improvement in PANSS positive score than patients not reporting 
this as a reason. Similar results were observed for the RAD mood items (per MADRS) 
and functional status (per QLS) as well as for corresponding analyses assessing reasons 
for continuation. Agreement between the clinician and patient scores was high (range 
73% to 100%). CONCLUSIONS: This initial psychometric assessment suggests the 
RAD is a valid tool for gathering detailed information regarding reasons for antipsy-
A556 4th Asia-Paciﬁ c Abstracts
chotic discontinuation and continuation from patients’ and clinicians’ perspectives. 
Further information is needed about the psychometric properties in usual care 
settings. 
PMH16
PHARMACIST-RUN METHADONE CLINIC IN A MALAYSIAN PUBLIC 
HEALTH CENTER: EVALUATING PATIENT SATISFACTION AND 
QUALITY OF LIFE OUTCOMES
Chiew GP1, Shaﬁ e AA2, Hassali MA2, Awaisu A2, Cheah WK3
1Larut Matang & Selama Health Ofﬁ ce, Taiping, Perak, Malaysia; 2Universiti Sains Malaysia, 
Minden, Penang, Malaysia; 3Hospital Taiping, Taiping, Malaysia
OBJECTIVES: To assess the satisfaction and health-related quality of life (HRQoL) 
improvement of patients enrolled in a pharmacist-run Methadone Maintenance 
Therapy (MMT) program. METHODS: A cohort study design was used to measure 
satisfaction and to evaluate changes in HRQoL of patients after one month of receiv-
ing methadone treatment at Taiping Health Clinic. Respondent’s satisfaction was 
measured by using an eight-item pre-validated questionnaire. A post-survey reliability 
analysis of the questionnaire showed a high internal consistency of the items (Cron-
bach’s α = 0.785). Meanwhile, the HRQoL was measured using a validated EQ-5D 
and EQ-VAS questionnaire that are administered by face-to-face interview in two 
phases, after 1 month interval. The data were analyzed by using both descriptive 
statistics (frequencies and percentages) and inferential statistics (χ2 test, paired t-test 
and the McNemar χ2 test). RESULTS: All 54 patients in MMT clinic participated, but 
only 40 (74.1%) completed this study. Average methadone dose in both phases were 
low (Phase One = 37.4 mg [SD = 22.2], Phase Two = 44.4 mg [SD = 21.3]) that caused 
majority of respondents wishing to increase their current dose. Respondents were not 
satisﬁ ed with needs to come clinic daily (n = 18, 33.4%) and did not believe that 
MMT clinic can help in cessation of drug abuse (n = 9, 16.7%). These two items were 
signiﬁ cantly associated with travelling distance of respondents to clinic (P = 0.001 and 
P = 0.039, respectively). Only pain/discomfort domain of the EQ-5D showed a sig-
niﬁ cant improvement from the baseline (P = 0.035). EQ-VAS score signiﬁ cantly 
improved from 64.69 (SD = 16.7) at baseline to 71.43 (SD = 14.9) during the 1-month 
follow-up (P = 0.008). CONCLUSIONS: MMT program was able to improve patients’ 
QoL even in short duration of time. Improvement on dissatisfactions toward travelling 
distance, needs to travel daily to clinic and inadequate dose will help to increase treat-
ment success. 
PMH17
COMPARISON OF HRQOL BETWEEN PATIENT RECEIVING 
METHADONE MAINTENANCE THERAPY (MMT) AND REHABILITATION 
PROGRAM
Abdul Ghani N, Shaﬁ e AA, Hassali MA
Universiti Sains Malaysia, Minden, Penang, Malaysia
OBJECTIVES: This study aims to compare the HRQoL between patients receiving 
methadone maintenance therapy (MMT) program with those in the rehabilitation 
program. METHODS: This was a cross-sectional study involving 400 randomly 
selected patients from two primary and secondary hospitals and one rehabilitation 
center (PUSPEN) in northern part of Malaysia. Consented patient was interviewed to 
collect their socio-demography, drug consumption and quality of life information. The 
quality of life was measured by using EQ-5D and EQ-VAS questionnaires. Their 
quality of life scores were then compared using independent t-test. RESULTS: Major-
ity of the participants were male with mean age 38.49 (SD = 9.6) in MMT group and 
34.77 (SD = 8.6) in rehabilitation group. Mean duration of treatment for MMT group 
was 17.5 months (SD = 15.74) and rehabilitation group was 7.8 months (SD = 3.52). 
EQ-5D score was signiﬁ cantly (P = 0.01) higher among MMT participants (mean = 
0.783, SD = 0.190) compared to those in rehabilitation program (mean = 0.707, SD 
= 0.227). Participants receiving MMT treatment also had lesser problems in mobility 
(10.5% vs. 21%; P < 0.01), normal activity (6.5% vs. 15%; P < 0.05) and anxiety 
(54.5% vs. 71%; P < 0.001). There was no statistically difference found between the 
groups in self care activity and pain dimensions. However, EQ-VAS score was signiﬁ -
cantly lower in MMT group compared to rehabilitation group (65.5 [SD = 17.9] vs. 
73.5 [SD = 17.6], P < 0.001). CONCLUSIONS: This study shows that treatment for 
patient with substance use disorder with MMT program can provide a better quality 
of life compared to rehabilitation program (PUSPEN). Variation seen between EQ-5D 
and EQ-VAS scores suggest that patients might perceived their health worst than the 
general population value. 
PMH18
THE EFFECT OF DIAGNOSED, SELF-REPORTED, AND AT-RISK 
DEPRESSION ON HEALTH-RELATED QUALITY OF LIFE AND WORK 
PRODUCTIVITY IN JAPAN AND EUROPE
DiBonaventura MD1, Fukuda T2, Nagae T3, Wagner JS1, Stankus A4
1Kantar Health, New York, NY, USA; 2Tokyo University, Tokyo, Japan; 3York Pharma KK, 
Tokyo, Japan; 4Kantar Health, Princeton, NJ, USA
OBJECTIVES: The aim of the current study was to establish the burden of depression 
(diagnosed, self-reported, and at-risk) in both Europe and Japan. METHODS: Data 
from the 2008 EU and 2008 Japan National Health and Wellness Survey (NHWS) 
were used. Patients were categorized into four groups: diagnosed depression, self-
reported depression, at-risk for depression, and controls. Differences among these 
groups were examined on quality of life (mental (MCS) and physical component 
summary (PCS) scores of the SF-12v2), as well as overall work impairment, controlling 
for demographics and patient characteristics. RESULTS: In the EU, 5848 patients 
(10.9%) were diagnosed, 2037 (3.8%) were self-reported, 13,168 (24.6%) were 
at-risk, and 32,471 (60.7%) were controls. In Japan, 884 (4.4%) were diagnosed, 162 
(0.8%) were self-reported, 5681 (28.4%) were at-risk, and 13,273 (66.4%) were 
controls. After controlling for demographics and patient characteristics, those with 
diagnosed depression (Adjusted Mean [Madj] = 34.4), self-reported depression (M—adj 
= 35.5), and at-risk depression (M—adj = 41.0) reported signiﬁ cantly lower levels of 
MCS scores than controls ((M—adj = 51.10, P’s < 0.0001) across all countries. The 
gap between controls and self-reported depression (b = 3.18, P < 0.0001) and at-risk 
depression (b = 0.63, P < 0.001) was signiﬁ cantly greater in Japan than in the EU. 
Both those with diagnosed (Madj = 46.2) and at-risk (M—adj = 49.4) depression 
reported signiﬁ cantly lower levels of PCS than controls (M—adj = 49.6, P’s < 0.05). 
Finally, those diagnosed with depression (M—adj = 39.2%), self-reported depression 
(M—adj = 30.9%), and at-risk for depression (M—adj = 23.3%) all reported signiﬁ cantly 
more overall work impairment than controls (M—adj = 12.8%). There was also a 
signiﬁ cant interaction, such that the difference in impairment between patients diag-
nosed with depression and controls was signiﬁ cantly greater in Japan (P < 0.05). 
CONCLUSIONS: Levels of diagnosed and self-reported depression were lower in 
Japan than in Europe, yet rates of at-risk depression were higher. Although the burden 
of depression was substantial, the results suggest that the work impairment burden in 
Japan is signiﬁ cantly greater than in the EU. 
PMH19
THE BURDEN OF DIAGNOSED, SELF-REPORTED, AND AT-RISK 
DEPRESSION IN CHINA AND EUROPE
DiBonaventura MD1, Liu GG2, Wagner JS1, Stankus A3
1Kantar Health, New York, NY, USA; 2Peking University, Beijing, China; 3Kantar Health, 
Princeton, NJ, USA
OBJECTIVES: The objective of this project was to assess the burden of depression in 
terms of quality of life and work impairment in the EU and China. METHODS: Data 
were obtained from the 2008 EU and 2009 China National Health and Wellness 
Survey (NHWS). Patients were categorized into four groups: diagnosed depression, 
self-reported depression, at-risk for depression, and controls. Differences among these 
groups were examined on quality of life (mental (MCS) and physical component 
summary (PCS) scores of the SF-12v2), as well as overall work impairment, controlling 
for demographics and patient characteristics. RESULTS: In the EU, 5848 patients 
(10.9%) were diagnosed, 2037 (3.8%) were self-reported, 13168 (24.6%) were 
at-risk, and 32471 (60.7%) were controls. In China, 339 (2.5%) were diagnosed, 348 
(2.6%) were self-reported, 3883 (29.2%) were at-risk, and 8752 (65.7%) were con-
trols. Adjusting for demographics and comorbidities, those with diagnosed (b = 
−16.00, P < 0.0001) and self-reported (b = −14.42, P < 0.0001) depression, and those 
at-risk for depression (b = −9.22, P < 0.0001) reported signiﬁ cantly lower MCS than 
controls. Those diagnosed (b = −3.62, P < 0.0001) and at-risk (b = −0.47, P = 0.0022) 
for depression reported signiﬁ cantly lower PCS than controls. In addition, the MCS 
difference between those with diagnosed, self-reported, or at-risk depression relative 
to controls was signiﬁ cantly greater in Europe than in China (b = 5.88, P < 0.0001; 
b = 5.60, P < 0.0001; b = 3.49, P < 0.0001, respectively). However, the PCS gap 
between patients at-risk for depression and controls was signiﬁ cantly greater in China 
than in Europe (b = −0.99, P < 0.0001). Finally, the work impairment gap between 
patients with diagnosed, self-reported, or at-risk depression and controls was signiﬁ -
cantly greater in Europe than in China (b = −0.35, P = 0.0002; b = −0.40, P < 0.0001; 
b = −0.08, P = 0.0455, respectively). CONCLUSIONS: Depression was associated 
with a substantial burden on patients. The impact of depression on mental quality of 
life and work impairment was greatest in Europe while the impact of depression on 
physical quality of life was greatest in China. 
MENTAL HEALTH – Health Care Use & Policy Studies
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SWITCHING BETWEEN SSRI BRANDS IN AUSTRALIA
Ortiz MS1, Calcino G2
1University of NSW, Darlinghurst, NSW, Australia; 2HI Connections, Canberra, ACT, 
Australia
OBJECTIVES: To study the extent of brand substitution and switching between Selec-
tive Serotonin Reuptake Inhibitors (SSRI) available on the Pharmaceutical Beneﬁ t 
Scheme (PBS). METHODS: PBS prescription claims data provided by Medicare Aus-
tralia of a 10% random sample of all Australian long-term concession card holders 
covering the time period August 2007 through July 2008 were assessed. Patients had 
to ﬁ ll at least four prescriptions for an SSRI with generics over the 1-year period 
(ﬂ uoxetine [2 doses forms with up to 12 brands], ﬂ uvoxamine [2 strengths with up 
to 5 brands], paroxetine [1 strength with 11 brands] and sertraline [2 strengths with 
up to 13 brands]). The proportions of non-switchers (single brand only) and multiple 
switchers (two or more switches between brands) were determined for each strength 
of each SSRI molecule. RESULTS: A total of 18,691 Concessional patients ﬁ lled at 
least four prescriptions for a SSRI in the 12-month time window. The majority of 
these patients received a single brand over the period: ranging from 49% for ﬂ uvox-
amine to 67% for ﬂ uoxetine. Only a small proportion received three or more brands: 
ranging from 12% for ﬂ uoxetine to 16% for ﬂ uvoxamine. The proportions of multiple 
switchers varied slightly between molecules with: 22% for ﬂ uoxetine, 32% for ﬂ u-
voxamine, 26% for paroxetine and 24% for sertraline. Switching was greater for 
